REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Conditions

• Cancer-Associated Thrombosis (CAT)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• REGN7508 — DRUG
  Administered per the protocol
• Placebo — DRUG
  Administered per the protocol

Study Details

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Key Dates

Start date

Mar 9, 2026

Status verified

May 2026

Primary completion

Jan 23, 2030

Completion

May 6, 2030

Study Design

Enrollment

1,120 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: REGN7508
• Placebo Comparator: Placebo

Primary Outcome Measure

Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death [ Time Frame: Through 6 months ]

Central Contacts

• Clinical Trials Administrator
  844-734-6643
  [email protected]

Locations (3)

Find similar trials in Hialeah, FL